Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + trastuzumab + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Pyrotinib + trastuzumab + nab-paclitaxel is a combination therapeutic regimen being investigated for the treatment of HER2-positive metastatic breast cancer with brain metastases. The regimen consists of pyrotinib, an orally bioavailable, irreversible pan-ErbB tyrosine kinase inhibitor (TKI) targeting HER2, EGFR, and HER4; trastuzumab, a recombinant humanized monoclonal antibody that targets the extracellular domain of the HER2 protein; and nab-paclitaxel (Abraxane), an albumin-bound nanoparticle formulation of the microtubule inhibitor paclitaxel. This combination is specifically being studied in a Phase 2 clinical trial led by the Shandong Cancer Hospital and Institute to evaluate its intracranial and extracranial efficacy in patients with HER2-positive breast cancer that has metastasized to the central nervous system. The triplet approach aims to overcome resistance and improve blood-brain barrier penetration through the small-molecule TKI component while maintaining systemic control with the antibody and chemotherapy components.
- Brand names
- AiRuiNiHerceptinAbraxane
- Other names
- Pyrotinib Plus Trastuzumab and AbraxanePyrotinib + Trastuzumab + nab-paclitaxel
02
Targets
ERBB4 (Erb-b2 receptor tyrosine kinase 4)TUBB (Tubulin (alpha and beta subunits))EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on pyrotinib + trastuzumab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + trastuzumab + nab-paclitaxel.